NCT05428150View on ClinicalTrials.gov

Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

September 25, 2022

Study Completion Date

September 25, 2022

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Esbriet 267 MG Oral Capsule

Reference Formulation

DRUG

EXCL-100, 600 MG Oral Tablet

Test Formulation

Trial Locations (1)

45227

Medpace Clinical Pharmacology Unit, Cincinnati

Sponsors
All Listed Sponsors
lead

Excalibur Pharmaceuticals, Inc.

INDUSTRY

NCT05428150 - Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers | Biotech Hunter | Biotech Hunter